These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7496729)
1. Pharmacokinetics of [3H]biotin bound to different avidin analogues. Kang YS; Saito Y; Pardridge WM J Drug Target; 1995; 3(2):159-65. PubMed ID: 7496729 [TBL] [Abstract][Full Text] [Related]
2. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate. Kang YS; Pardridge WM J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841 [TBL] [Abstract][Full Text] [Related]
3. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. Yoshikawa T; Pardridge WM J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Kang YS; Bickel U; Pardridge WM Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897 [TBL] [Abstract][Full Text] [Related]
5. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). Jeong Lee H; Pardridge WM J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. Wu D; Boado RJ; Pardridge WM J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. Kang YS; Boado RJ; Pardridge WM Drug Metab Dispos; 1995 Jan; 23(1):55-9. PubMed ID: 7720525 [TBL] [Abstract][Full Text] [Related]
8. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Kang YS; Pardridge WM Pharm Res; 1994 Sep; 11(9):1257-64. PubMed ID: 7816753 [TBL] [Abstract][Full Text] [Related]
9. Stability of the disulfide bond in an avidin-biotin linked chimeric peptide during in vivo transcytosis through brain endothelial cells. Kang YS; Voigt K; Bickel U J Drug Target; 2000; 8(6):425-34. PubMed ID: 11328668 [TBL] [Abstract][Full Text] [Related]
10. Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Muzykantov VR; Murciano JC; Taylor RP; Atochina EN; Herraez A Anal Biochem; 1996 Oct; 241(1):109-19. PubMed ID: 8921172 [TBL] [Abstract][Full Text] [Related]
11. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Deguchi Y; Kurihara A; Pardridge WM Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961 [TBL] [Abstract][Full Text] [Related]
12. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate. Li XB; Liao GS; Shu YY; Tang SX J Nat Toxins; 2000 Feb; 9(1):73-83. PubMed ID: 10701183 [TBL] [Abstract][Full Text] [Related]
13. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488 [TBL] [Abstract][Full Text] [Related]
14. Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein. Lehtolainen P; Wirth T; Taskinen AK; Lehenkari P; Leppänen O; Lappalainen M; Pulkkanen K; Marttila A; Marjomäki V; Airenne KJ; Horton M; Kulomaa MS; Ylä-Herttuala S Gene Ther; 2003 Dec; 10(25):2090-7. PubMed ID: 14595382 [TBL] [Abstract][Full Text] [Related]
15. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853 [TBL] [Abstract][Full Text] [Related]
16. Immobilized nitro-avidin and nitro-streptavidin as reusable affinity matrices for application in avidin-biotin technology. Morag E; Bayer EA; Wilchek M Anal Biochem; 1996 Dec; 243(2):257-63. PubMed ID: 8954558 [TBL] [Abstract][Full Text] [Related]
17. Extension of the single amino acid chelate concept (SAAC) to bifunctional biotin analogues for complexation of the M(CO)3(+1) Core (M = Tc and Re): syntheses, characterization, biotinidase stability, and avidin binding. James S; Maresca KP; Allis DG; Valliant JF; Eckelman W; Babich JW; Zubieta J Bioconjug Chem; 2006; 17(3):579-89. PubMed ID: 16704194 [TBL] [Abstract][Full Text] [Related]
18. Avidin-biotin system: a small library of cysteine biotinylated derivatives designed for the [99mTc(N)(PNP)]2+ metal fragment. Bolzati C; Caporale A; Agostini S; Carta D; Cavazza-Ceccato M; Refosco F; Tisato F; Schievano E; Bandoli G Nucl Med Biol; 2007 Jul; 34(5):511-22. PubMed ID: 17591551 [TBL] [Abstract][Full Text] [Related]
19. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. Wu D; Pardridge WM J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978 [TBL] [Abstract][Full Text] [Related]
20. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. Rosebrough SF; Hartley DF J Nucl Med; 1996 Aug; 37(8):1380-4. PubMed ID: 8708779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]